neurology

News

Alzheon Alzheimer's hopes dented by trial readout

Alzheon has been left sifting through data from a failed Alzheimer's trial for crumbs of evidence that its oral therapy may have some efficacy.

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

News

Prof Vanessa Raymont of the University of Oxford

UK sets aside £2m for digitally-enhanced dementia tests

The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.

News

End of the line for Cassava's troubled Alzheimer's programme

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.

News

Augustine decloaks with $85m for nerve disease programme

Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.

Alzheon Alzheimer's hopes dented by trial readout

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

UK sets aside £2m for digitally-enhanced dementia tests

End of the line for Cassava's troubled Alzheimer's programme

Augustine decloaks with $85m for nerve disease programme

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

neurology

Editor's Picks